EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
Hand-out
Press Releases
December 7, 2024

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PROVIDENCE, R.I., Dec. 6, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service

bradford

The Bradford Era

Local & Social